Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

Fig. 2

Gene expression of the STING downstream effector chemokine CCL5 is correlated with the expression of NK cell-related genes, such as FCGR3A and NKG7 (NK cell receptors) and PRF1 (perforin, a marker of NK cell activation), with Spearman Rho> 0.5 (p < 0.001) in the TCGA lung adenocarcinoma cohort (n = 511). B. Comparison of differential gene expression between POLE mutant versus POLE wild-type lung adenocarcinoma (n = 511) or squamous carcinoma (n = 501) from the TCGA dataset revealed significant higher levels of STING genes (FC ≥ 1.5; P < 0.05 by T-test). C. The Table summarizes results from comparison of differential gene expression for STING/immune signatures genes between DDR mutant and DDR wild-type NSCLC: immune genes, that are correlated to immunotherapy response, with a FC ≥ 1.5 in DDR mutant samples are presented (P < 0.05 by T-test)

Back to article page